PKC COMPLETES SUCCESSFUL PROOF OF CONCEPT OF OPTICAL LAB-ON-A-CHIP

INGLEWOOD, CALIFORNIA, April 2, 2009 – Pharmaco-Kinesis Corporation, an advanced medical device company developing smart local drug delivery systems, today announced the successful completion of proof-of-concept of a novel optical lab-on-a-chip that detects varying levels of Vascular Endothelial Growth Factor (VEGF) in cerebral fluid.

The optical lab-on-a-chip measures UV photon absorption to provide real-time quantification of VEGF secreted by the tumor. This novel technology is an integral component of the Magnetic Breather Pump (MBP) under development at Pharmaco-Kinesis. Josh Shachar, Founder, Director and Chairman of the Scientific Advisory Board of Pharmaco-Kinesis stated, “The MBP represents a major advance in treatment of malignant gliomas and other aggressive brain tumors. By using a highly integrated and compact “bio-lab,” the MBP is expected to enable physicians to control through wireless remote technology the local delivery of several tumor fighting medications in response to real time measurement of VEGF and other biological factors.”

Frank Adell, President and CEO of Pharmaco-Kinesis furthered, “We look forward to achieving several additional milestones in the near future as we continue the development of the optical lab-on-a-chip and other advanced components of the MBP.” Under the direction of Thomas C. Chen, M.D., Ph.D., Chief Oncology Officer, the Company is working on the MBP and additional novel technologies for smart local delivery of medication and measurement of biological responses.

For additional information, please contact:
Daniel Saks Senior
Vice President, Corporate Affairs
Pharmaco-Kinesis Corporation
(310) 734-4447